Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.62 |
| ▸ | MET | P08581 | 7/20 | 0.62 |
| ▸ | TEK | Q02763 | 7/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.62 |
| ▸ | AURKA | O14965 | 5/20 | 0.62 |
| ▸ | LCK | P06239 | 3/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 8/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.55 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | FLT1 | P17948 | 2/20 | 0.55 |
| ▸ | FLT4 | P35916 | 2/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | STK10 | O94804 | 1/20 | 0.55 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19956995 | 0.94 | KDR (0.60) | KDRMETTEKAURKBAURKA | |
| SCHEMBL30102506 | 0.92 | KDR (0.52) | KDRMETTEKAURKBAURKA | |
| SCHEMBL1891385 | 0.86 | PDGFRB (0.64) | KDRPDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL19957430 | 0.82 | KDR (0.74) | KDRMETTEKAURKBAURKA | |
| SCHEMBL23128557 | 0.81 | KDR (0.60) | KDRMETTEKAURKBAURKA | |
| SCHEMBL1890626 | 0.80 | KDR (0.70) | KDRMETTEKAURKBAURKA | |
| SCHEMBL29186593 | 0.80 | KDR (0.69) | KDRMETTEKAURKBAURKA | |
| SCHEMBL31218163 | 0.79 | KDR (0.71) | KDRMETTEKAURKBAURKA | |
| SCHEMBL14967325 | 0.79 | PDGFRA (0.74) | KDRMETTEKAURKBAURKA | |
| SCHEMBL1893450 | 0.79 | KDR (0.68) | KDRMETTEKAURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| CN-112384506-B | Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20210188806-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-24 | — | — | US | disclosed |
| US-20210188806-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-24 | — | — | US | disclosed |
| EP-3795567-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2021-03-24 | — | — | EP | disclosed |
| EP-3795567-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2021-03-24 | — | — | EP | disclosed |
| CN-112384506-A | Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | KDR 150/4885MET 159/4885TEK 155/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | KDR 150/4885MET 159/4885TEK 155/4885 |
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | FLT1, KDR, TEK | KDR 2/4885MET 11/4885TEK 3/4885 |
| US-20210188806-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | FLT1, KDR, TEK | KDR 2/4885MET 11/4885TEK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.